Fig. 6
Bootstrap Distribution of Cost-Effectiveness: Risankizumab vs. Adalimumab, Assuming Weekly Dosing, Cheapest Biosimilar for Adalimumab, and a 40% Public Price Reduction for Risankizumab
Fig. 6 | Cost Effectiveness and Resource Allocation